NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
21.76
-0.65 (-2.90%)
At close: Mar 28, 2025, 4:00 PM
20.86
-0.90 (-4.13%)
Pre-market: Mar 31, 2025, 7:40 AM EDT
NAMS Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for NAMS stock have an average target of 43.17, with a low estimate of 37 and a high estimate of 52. The average target predicts an increase of 98.39% from the current stock price of 21.76.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 27, 2025.
Analyst Ratings
The average analyst rating for NAMS stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Maintains $47 → $52 | Buy | Maintains | $47 → $52 | +138.97% | Feb 27, 2025 |
| Needham | Needham | Strong Buy Maintains $46 → $42 | Strong Buy | Maintains | $46 → $42 | +93.01% | Feb 27, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $40 | Buy | Reiterates | $40 | +83.82% | Jan 28, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $40 | Buy | Reiterates | $40 | +83.82% | Jan 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $48 | Strong Buy | Reiterates | $48 | +120.59% | Jan 14, 2025 |
Financial Forecast
Revenue This Year
16.88M
from 45.56M
Decreased by -62.95%
Revenue Next Year
17.31M
from 16.88M
Increased by 2.54%
EPS This Year
-1.87
from -2.56
EPS Next Year
-1.92
from -1.87
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 31.5M | 63.0M | 424.4M | ||
| Avg | 16.9M | 17.3M | 146.7M | ||
| Low | n/a | n/a | 34.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -30.9% | 273.2% | 2,351.5% | ||
| Avg | -62.9% | 2.5% | 747.6% | ||
| Low | - | - | 98.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.62 | -1.31 | -0.43 | ||
| Avg | -1.87 | -1.92 | -1.49 | ||
| Low | -2.07 | -2.31 | -2.44 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.